CME

$CME

CME Group Inc.

World's largest derivatives marketplace for futures and options.

Finance
$306.31
-3.94 (-1.27%)
Day Range$306.05 - $309.67
Prev Close$310.25

CME key facts as of November 14, 2026

Latest AI research report
CME Group: Valuation, Volume and Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Buy (5 Strong Buy, 4 Buy, 6 Hold, 1 Sell, 1 Strong Sell) (as of November 1, 2026)
Analyst price target
$317.91 mean (range $227.00 to $367.00) (as of November 20, 2026)
Sector
Finance
Analyst Rating
Buy
9 Buy / 6 Hold / 2 Sell
Price Target
$317.91
3.8% upside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

NEUTRAL

CME Group: Valuation, Volume and Risks

CME Group reported a quarterly earnings beat and set a new volume record in Lean Hog futures and options, while revenue and earnings growth remain positive in the available data. Its share price is close to the analyst mean target, leaving valuation, trading activity and macroeconomic conditions central to the outlook.

Nov 14, 2026

CME FAQ

What is StockAlpha's latest view on CME?

StockAlpha's latest AI research report on CME Group Inc. (CME), "CME Group: Valuation, Volume and Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. CME Group reported a quarterly earnings beat and set a new volume record in Lean Hog futures and options, while revenue and earnings growth remain positive in the available data. Its share price is close to the analyst mean target, leaving valuation, trading activity and macroeconomic conditions central to the outlook.

When was the CME research last updated?

The most recent CME report was published on November 14, 2026.

What do analysts expect for CME?

As of November 1, 2026, the analyst consensus on CME is Buy (5 Strong Buy, 4 Buy, 6 Hold, 1 Sell, 1 Strong Sell). As of November 20, 2026, the analyst price target is $317.91 mean (range $227.00 to $367.00).

Is this CME research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring